Omeros
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.
Nura, Inc. is focused on discovering and developing pharmaceuticals aimed at treating neurodegenerative diseases and behavioral disorders. The company specializes in therapeutics that target G Protein-coupled receptors (GPCR) and phosphodiesterase (PDE) enzymes expressed in the brain. Nura’s research includes programs for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, depression, anxiety, obesity, and addiction, as well as attention-deficit hyperactivity disorder and pain. Through its innovative approach, Nura aims to address significant unmet medical needs in these areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.